The development of artificial vision began with occipital cortex prosthesis, though the retinal prosthesis has advanced faster over recent years ( Fernandes et al., 2012). The captivating wish that technology may someday allow us to excel our physical limitations has long been with scientists, doctors and the public at large. The residual inner retinal cells have prompted efforts to develop retinal prostheses to stimulate the surviving neural retinal cells and possibly restore functional vision.ĭevices used to restore vision loss have long been ideas for science fictions. RP leads to degeneration of the photoreceptor layer of the retina, and while the condition is assumed to be linked to over 200 RP-causing mutations, they occur in almost 25 genes and a count of over 120 loci ( Sohocki et al., 2001 Hagiwara et al., 2011). The inherited retinal disease known as Retinitis Pigmentosa (RP) has an estimated prevalence of 1 in 4000 worldwide ( Hartong et al., 2006). Insights from this report were communicated during the first “Brain Engineering and Computational Neuroscience Conference,” 31 January-2 February 2018 in Tehran. This technology report paper has been an attempt to provide an overview of Argus-II retinal implant global experience as well as the clinical outcome of the so far cases in Iran. As such, establishing a collaborative network will foster organized research efforts to better define outcome assessment and rehabilitation strategies. A multidisciplinary approach within a cross-functional team would optimize strategies toward better patient outcomes. Beside successful surgery and post-operative care, rehabilitation efforts with validated outcome measures including visual rehabilitation together with neurovisual, visuo-constructive and cognitive rehabilitation/empowerment approaches are expected to boost the functional outcome. To date, Argus II artificial retina is implanted in four patients in Iran. The first Argus II retinal prosthesis in Iran was successfully implanted in Shiraz (October 2017). The global experience with Argus II has enrolled no more than 300 cases so far. To obtain better results, expectation counseling and preoperative retinal assessment are critical. Compared to gene therapy Argus II is less costly with a demonstrated favorable outcome, though the vision is yet artificial. Over the past few years, visual prostheses (namely, Argus II retinal implant) and gene therapy have obtained FDA approval in treating blindness resulting from retinitis pigmentosa. 6DANA Brain Health Institute, Iranian Neuroscience Society, Fars Chapter, Shiraz, Iran.5Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. 4Students' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.3Computer Engineering Department, Sharif ICT Innovation Center, Sharif University of Technology, Tehran, Iran.1Department of Ophthalmology, Poostchi Ophthalmology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.Hossein Nowroozzadeh 1 †, Feisal Rahat 2 †, Hossein Peyvandi 3 †, Reza Farvardin 4 and Mohammad Nami 5,6 * Mohsen Farvardin 1,2, Mehrdad Afarid 1 †, Adel Attarzadeh 2 †, Mohammad K.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |